Graft-versus-Host Disease Prophylaxis with PostTransplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: WFRF:(Apperley Jane F.) > Graft-versus-Host D...

LIBRIS Formathandbok (Information om MARC21)

Details
MARC

Fältnamn	Indikatorer	Metadata
000		06086naa a2200673 4500
001		oai:DiVA.org:uu-524336
003		SwePub
008		240301s2024 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5243362 URI
024	7	a https://doi.org/10.1016/j.jtct.2023.09.0192 DOI
040		a (SwePub)uu
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Ortí, Guillermou Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Hematol, Barcelona, Spain.4 aut
245	1 0	a Graft-versus-Host Disease Prophylaxis with PostTransplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor :b A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)
264	1	b Elsevier,c 2024
338		a print2 rdacarrier
520		a Outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) for chronic myeloid leukemia (CML) with post-transplantation cyclophosphamide (PTCy) using an unrelated donor (UD) or a mismatched related donor (MMRD) remain unknown. We report a retrospective comparison of PTCy-based allo-HCT from a UD, non-PTCy allo-HCT from a UD, and PTCy allo-HCT from an MMRD. Inclusion criteria were adult patients with CML undergoing first allo-HCT between 2012 and 2019 from a UD with either PTCy or non-PTCy graft-versus-host disease (GVHD) prophylaxis or from an MMRD using PTCy. The primary endpoint was GVHD-free/relapse-free survival (GRFS). A total of 1341 patients were included (82% in the non-PTCy UD cohort). With a median follow-up of 34.9 months, the 3-year GRFS was 43% in the non-PTCy cohort, 37% in the PTCy-UD cohort, and 39% PTCy-MMRD cohort (P = .15). Multivariable analyses revealed no significant differences among the 3 cohorts in terms of overall survival (OS), progression-free survival, RI, and nonrelapse mortality. Factors independently associated with worse OS in the overall cohort were Karnofsky Performance Status <90 (hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.41 to 2.45; P < .001), older age (HR, 1.24, 95% CI, 1.11 to 1.38; P < .001), and disease stage (compared to chronic phase [CP] 1): blast phase (HR, 2.25; 95% CI, 1.60 to 3.16; P < .001), accelerated phase (HR, 1.63; 95% CI, 1.05 to 2.54; P = .03), and CP >2 (HR, 1.58; 95% CI, 1.15 to 2.17; P = .005). These results suggest that allo-HCT in patients with CML using either a UD or an MMRD with PTCy-based GVHD prophylaxis are feasible transplantation, platforms and that the disease stage at allo-HCT remains a major prognostic factor, highlighting the importance of closely monitoring CML patients and proposing transplantation when indicated when still in CP1.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
653		a Allogeneic hematopoietic cell transplantation
653		a Chronic myeloid
653		a leukemia
653		a Post-transplantation
653		a cyclophosphamide
653		a Unrelated donor
653		a Haploidentical donor
700	1	a Gras, Luuku EBMT Stat Unit, Leiden, Netherlands.4 aut
700	1	a Koster, Lindau EBMT Leiden Study Unit, Leiden, Netherlands.4 aut
700	1	a Kulagin, Aleksanderu Pavlov Univ, RM Gorbacheva Res Inst, St Petersburg, Russia.4 aut
700	1	a Byrne, Jennyu Univ Nottingham, Nottingham, England.4 aut
700	1	a Apperley, Jane F.u Imperial Coll, London, England.4 aut
700	1	a Halaburda, Kazimierzu Inst Hematol & Transfus Med, Warsaw, Poland.4 aut
700	1	a Blau, Igor Wolfgangu Charite Univ Med Berlin, Berlin, Germany.4 aut
700	1	a Clark, Andrewu Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland.4 aut
700	1	a Kröger, Nicolausu Univ Hosp Eppendorf, Hamburg, Germany.4 aut
700	1	a Griskevicius, Laimonasu Vilnius Univ Hosp, Vilnius, Lithuania.4 aut
700	1	a Carlson, Kristinau Univ Hosp, Uppsala, Sweden4 aut0 (Swepub:uu)krica965
700	1	a Collin, Matthewu Northern Ctr Bone Marrow Transplantat, Newcastle Upon Tyne, Tyne & Wear, England.4 aut
700	1	a Bloor, Adrianu Christie NHS Trust Hosp, Manchester, Lancs, England.4 aut
700	1	a Raiola, Anna Mariau IRCCS Osped Policlin San Martino, Genoa, Italy.4 aut
700	1	a Blaise, Didieru Programme Transplantat & Therapie Cellulaire, Marseille, France.4 aut
700	1	a Aljurf, Mahmoudu King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia.4 aut
700	1	a López-Corral, Luciau Hosp Univ Salamanca, Dept Hematol, IBSAL, CIBERONC, Salamanca, Spain.4 aut
700	1	a Sakellari, Ioannau George Papanicolaou Gen Hosp, Thessaloniki, Greece.4 aut
700	1	a Beguin, Yvesu Univ Liege, Liege, Belgium.;CHU Liege, Liege, Belgium.4 aut
700	1	a Wrobel, Tomaszu Wroclaw Med Univ, Wroclaw, Poland.4 aut
700	1	a de Rosa, Lucau Osped S Camillo Forlanini, Rome, Italy.4 aut
700	1	a de Lavallade, Hughesu Guys & St Thomas NHS Fdn Trust, London, England.4 aut
700	1	a Hayden, Patrick J.u Trinity Coll Dublin, St Jamess Hosp, Dublin, Ireland.4 aut
700	1	a McLornan, Donalu Univ Coll Hosp, London, England.4 aut
700	1	a Chalandon, Yvesu Univ Geneva, Hop Univ Geneva, Div Hematol, Geneva, Switzerland.;Univ Geneva, Hop Univ Geneve, Fac Med, Geneva, Switzerland.4 aut
700	1	a Yakoub-Agha, Ibrahimu Univ Lille, CHU Lille, INSERM, U1286,Infinite, F-59000 Lille, France.4 aut
710	2	a Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Hematol, Barcelona, Spain.b EBMT Stat Unit, Leiden, Netherlands.4 org
773	0	t Transplantation and Cellular Therapyd : Elsevierg 30:1, s. 93.e1-93.e12q 30:1<93.e1-93.e12x 2666-6375x 2666-6367
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-524336
856	4 8	u https://doi.org/10.1016/j.jtct.2023.09.019

Find in a library

Transplantation and Cellular Therapy (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Hematology

Articles in the publication: Transplantation ...

By the university: Uppsala University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se